Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.47 |
| ▸ | TUBB | P07437 | 3/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29285813 | 0.81 | CA1 (0.49) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL862980 | 0.79 | POLB (0.73) | SMN1; SMN2TSHRPOLBMAPK1PTGS2 | |
| SCHEMBL4879136 | 0.78 | MAPT (0.47) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30989179 | 0.78 | ALDH1A1 (0.62) | TSHRPOLBLMNACYP2C9 | |
| SCHEMBL29285835 | 0.76 | PDE4A (0.64) | SMN1; SMN2POLBMAPK1 | |
| SCHEMBL29285658 | 0.76 | L3MBTL1 (0.67) | SMN1; SMN2TSHRLMNA | |
| SCHEMBL30989141 | 0.76 | PDE4A (0.64) | SMN1; SMN2POLBMAPK1 | |
| SCHEMBL26414908 | 0.76 | BRD4 (0.53) | KCNH2 | |
| SCHEMBL7412893 | 0.76 | SMN1; SMN2 (0.67) | SMN1; SMN2TSHRPOLBMAPK1PTGS2 | |
| SCHEMBL7092074 | 0.75 | SMN1; SMN2 (0.61) | SMN1; SMN2TUBB1TSHRPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2978754-B1 | BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-10 | — | — | EP | disclosed |
| EP-2978747-B1 | BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-04-19 | — | — | EP | disclosed |
| US-9199947-B2 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-12-01 | — | — | US | disclosed |
| US-9199947-B2 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-12-01 | — | — | US | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-9150526-B2 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-10-06 | — | — | US | disclosed |
| US-9150526-B2 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-10-06 | — | — | US | disclosed |
| WO-2014154726-A1 | BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296239-A1 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296296-A1 | Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140296239-A1 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2014154727-A1 | BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296296-A1 | Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| EP-2726465-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | Elan Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2012162254-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | SMN1; SMN2 576/4885ENPP2 4021/4885TUBB4A 3408/4885 |
| US-20140296239-A1 | Biaryl-propionic acid derivatives and their use as pharmaceuticals | CTSV, F2R, CTSF | SMN1; SMN2 4613/4885ENPP2 243/4885TUBB4A 2125/4885 |
| US-20140296296-A1 | Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals | CTSV, F2R, CTSF | SMN1; SMN2 4613/4885ENPP2 243/4885TUBB4A 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.